CN Patent

CN105378110B — 与癌症相关的基因融合体和基因变异体

Assigned to Life Technologies Corp · Expires 2024-06-25 · 2y expired

What this patent protects

本发明提供基因融合体、基因变异体和与疾病病况的新颖相关性以及使用其的试剂盒、探针和方法。

USPTO Abstract

本发明提供基因融合体、基因变异体和与疾病病况的新颖相关性以及使用其的试剂盒、探针和方法。

Drugs covered by this patent

larotrectinib-sulfate (LAROTRECTINIB SULFATE)

Patent Metadata

Patent number: CN105378110B
Jurisdiction: CN
Classification: —
Expires: 2024-06-25
Drug substance claim: No
Drug product claim: No
Assignee: Life Technologies Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.